… ProQR Announces an Investor and Analyst Event and … LEIDEN, Netherlands, Oct. 1, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … information or to RSVP, please contact Sariette Witte at ir@proqr.com . OTS The abstract titled: 'QR-010 penetrates …
… ProQR to present QR-010 data at the European Cystic Fibrosis … QR-010 can treat all manifestations of CF,” said Noreen R. Henig, MD, Chief Medical Officer of ProQR. “I am very pleased that enrollment of the Phase 1b …
… ProQR Announces an Investor and Analyst Event and … LEIDEN, Netherlands, April 25, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … molecule that will move into clinical development using ProQR’s RNA approach. ARVO The p.Cys998X mutation which is a …
… ProQR to Present Interim Phase 1/2 Results for QR-110 in … and will be made available in the “Investors” section of ProQR’s website ( www.proqr.com ) under “Events and Presentations”. About …
… ProQR Announces Positive Interim Results from Phase 1/2 … & CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … executive vice president of research and development of ProQR. “We observed a clinically meaningful improvement in …
… ProQR annonce des résultats intermédiaires positifs pour un … Massachusetts, 05 sept. 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), une entreprise qui … vice-président exécutif recherche et développement de ProQR. « Nous avons observé une amélioration cliniquement …
… proprietary Axiomer RNA-editing platform technology. Our ProQRians, representing over 30 nationalities, are passionate … to change the lives of patients and their loved ones. ProQR Therapeutics is a biotech company with offices in …
